COLL
HealthcareCollegium Pharmaceutical, Inc. · Drug Manufacturers - Specialty & Generic · $1B
What is Collegium Pharmaceutical, Inc.?
Collegium Pharmaceutical is a specialty pharmaceutical company focused on pain management medicines. Headquartered in Stoughton, Massachusetts, it commercializes a portfolio of opioid-based therapies designed with abuse-deterrent and extended-release formulations.
Collegium generates revenue by selling prescription pain medications to healthcare providers across the United States. Its business model centers on commercializing differentiated opioid formulations — particularly abuse-deterrent and extended-release products — that address the needs of patients requiring around-the-clock, long-term pain treatment. Rather than broad drug discovery, the company focuses on specialty pharmaceutical development and targeted sales efforts within the pain management segment.
Collegium Pharmaceutical was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
- Xtampza ER — abuse-deterrent extended-release oxycodone formulation
- Nucynta ER — extended-release tapentadol for chronic pain
- Nucynta IR — immediate-release tapentadol for acute pain
- Abuse-deterrent technology platform across opioid products
Is COLL a Good Stock to Buy?
UQS Score rates COLL as Good overall, reflecting a mixed profile across its five quality pillars.
The Quality pillar comes in at a Good rating, suggesting the business generates reasonable financial returns relative to its size and sector. Valuation is rated Attractive, meaning the stock does not appear richly priced compared to its fundamentals — a notable characteristic for a small-cap specialty pharma name.
The Moat and Risk pillars both register as Weak, pointing to limited competitive insulation and meaningful business or financial risks that investors should weigh carefully. Growth is rated Neutral, indicating the company is not currently demonstrating an accelerating expansion trajectory.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does COLL pay dividends?
No — Collegium Pharmaceutical, Inc. does not currently pay a dividend.
Collegium Pharmaceutical does not currently pay a dividend. This is common among specialty pharmaceutical companies of its size, where capital is typically directed toward commercial operations, debt management, and potential pipeline or portfolio expansion rather than shareholder distributions.
When does COLL report earnings?
Collegium Pharmaceutical reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Quarterly results for specialty pharma companies like Collegium tend to reflect prescription volume trends, gross-to-net adjustments, and operating expense discipline. Investors should monitor how the core pain-management portfolio performs relative to competitive and regulatory pressures each quarter.
For the most recent quarter's results and guidance, visit Collegium Pharmaceutical's investor relations page directly.
COLL Price History
+39.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Collegium Pharmaceutical, Inc.?
Based on Collegium Pharmaceutical, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
COLL Long-term Outlook
With a Neutral Growth pillar and Weak Risk rating, Collegium's near-term fundamental outlook is cautious. The company's revenue base is tied to a mature pain-management category subject to regulatory scrutiny and generic competition, which constrains visible upside. That said, the Attractive Valuation label suggests the market may already be pricing in these headwinds, leaving room for re-rating if execution improves.
Growth drivers
- Continued prescription uptake of Xtampza ER as an abuse-deterrent alternative
- Potential portfolio expansion through licensing or acquisition of complementary pain assets
- Operational leverage as commercial infrastructure costs stabilize
Key risks
- Regulatory and legislative pressure on opioid prescribing practices
- Generic or branded competition eroding market share in pain management
- Weak Moat rating signals limited pricing power and switching barriers
COLL vs Peers
Collegium operates in a competitive specialty pharmaceutical landscape alongside companies with distinct business models and therapeutic focuses.
Tilray operates across cannabis and consumer beverage categories, giving it a very different revenue profile than Collegium's prescription opioid focus.
Pacira focuses on non-opioid postsurgical pain solutions, positioning it as a philosophically contrasting approach to pain management versus Collegium's opioid portfolio.
Alvotech is a biosimilar developer targeting biologic drugs, competing in a different pharmaceutical segment but sharing the specialty pharma risk profile.
Frequently Asked Questions
What does Collegium Pharmaceutical do?
Collegium Pharmaceutical develops and commercializes prescription medicines for pain management. Its portfolio centers on abuse-deterrent and extended-release opioid formulations, including Xtampza ER and the Nucynta franchise, sold to healthcare providers across the United States.
Does COLL pay dividends?
No, Collegium Pharmaceutical does not currently pay a dividend. The company reinvests available capital into its commercial operations and balance sheet rather than distributing cash to shareholders — a common approach for small-cap specialty pharma companies.
When does COLL report earnings?
Collegium reports earnings quarterly, in line with standard US-listed company practice. For exact dates and the most recent results, check the investor relations section of Collegium Pharmaceutical's official website.
Is COLL a good stock to buy?
UQS Score rates COLL as Good overall. The Valuation pillar is Attractive and Quality is rated Good, but the Moat and Risk pillars are both Weak. Whether that profile suits your portfolio depends on your risk tolerance and investment horizon. View the full pillar breakdown on UQS Pro.
Is COLL overvalued?
Based on the UQS Valuation pillar, COLL is rated Attractive — meaning the stock does not appear overpriced relative to its fundamentals. However, valuation alone does not determine investment merit; the Weak Moat and Risk ratings are important context.
How does COLL compare to its competitors?
Collegium's closest peers in the specialty pharma and pain-management space include Pacira BioSciences, Tilray Brands, and Alvotech. Each operates with a distinct business model. UQS Pro members can view side-by-side pillar comparisons across these names.
What is COLL's market cap bracket?
Collegium Pharmaceutical is classified as a small-cap company. Small-cap specialty pharma stocks typically carry higher volatility and concentration risk than large-cap peers, which is consistent with the Weak Risk pillar rating COLL carries.
Who founded Collegium Pharmaceutical?
Collegium Pharmaceutical was incorporated in 2002. Founding details and leadership history are publicly available through the company's official filings and investor relations materials on its website.
Is COLL a long-term quality investment?
As a long-term quality indicator, COLL's Good overall UQS Score reflects a mixed picture. The Attractive Valuation and Good Quality ratings are positives, but the Weak Moat suggests limited durable competitive advantages — a factor that matters significantly over longer holding periods.
What is the main competitive advantage of Collegium Pharmaceutical?
Collegium's primary differentiation lies in its abuse-deterrent formulation technology applied to opioid products. However, the UQS Moat pillar rates this advantage as Weak, suggesting the company faces meaningful competitive and regulatory pressures that limit the durability of that edge.
What sector does COLL belong to?
Collegium Pharmaceutical operates in the Healthcare sector, specifically within specialty pharmaceuticals. The company focuses on the pain management sub-segment, which is subject to distinct regulatory oversight compared to other pharmaceutical categories.
Is COLL a growth stock or value stock?
Based on UQS pillar labels, COLL leans toward value characteristics — the Valuation pillar is Attractive while Growth is rated Neutral. This suggests the stock may appeal more to value-oriented investors than those seeking high-growth momentum.
Unlock Full COLL Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS pillar scores across all five dimensions
- ✓Access complete financial metrics and trend data
- ✓Compare COLL side-by-side with sector peers
- ✓Screen for Attractive-valuation small-cap healthcare stocks
- ✓Get the full analyst-style quality breakdown for COLL
Pro Analysis
COLL — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 16, 2026 | 56.4 | 73.1 | 28.0 | 57.8 | 30.6 | 100.0 | +0.7 |
| May 11, 2026 | 55.7 | 73.1 | 28.0 | 54.2 | 30.6 | 100.0 | -0.2 |
| May 10, 2026 | 55.9 | 73.7 | 28.0 | 54.2 | 30.6 | 100.0 | -0.4 |
| May 8, 2026 | 56.3 | 73.0 | 28.0 | 57.0 | 31.0 | 100.0 | +1.2 |
| Apr 26, 2026 | 55.1 | 70.4 | 28.0 | 57.0 | 27.6 | 100.0 | +2.0 |
| Apr 2, 2026 | 53.1 | 70.4 | 28.0 | 46.8 | 27.6 | 100.0 | — |
COLL — Pillar Breakdown
Quality
— 73.1/100 (25%)Collegium Pharmaceutical, Inc. shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 57.8/100 (20%)Collegium Pharmaceutical, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 30.6/100 (15%)Collegium Pharmaceutical, Inc. presents elevated risk with concerns around leverage or financial stability.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 100.0/100 (15%)Collegium Pharmaceutical, Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 28/100 (25%)Collegium Pharmaceutical, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for COLL.
Score Composition
Financial Data
More Stock Analysis
How is the COLL UQS Score Calculated?
The UQS (Unified Quality Score) for Collegium Pharmaceutical, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Collegium Pharmaceutical, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Collegium Pharmaceutical, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.